{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:19:36Z","timestamp":1758050376266,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bulcan.2023.10.006","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T15:37:35Z","timestamp":1707320255000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["La chimioth\u00e9rapie intra-p\u00e9riton\u00e9ale dans le traitement de la carcinose p\u00e9riton\u00e9ale d\u2019origine colorectale. CHIP, PIPAC, \u00e9tat des lieux et perspectives"],"prefix":"10.1016","volume":"111","author":[{"given":"Fran\u00e7ois","family":"Qu\u00e9net","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Carr\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.10.006_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tgh.2016.08.03","article-title":"Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy\/hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"1","author":"Ji","year":"2016","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0240","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0245","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0250","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523\u00a0patients from a multicentric French study","volume":"28","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0260","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0265","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0270","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1245\/s10434-010-1522-1","article-title":"Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study","volume":"18","author":"Chua","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0275","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539\u00a0patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0280","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0285","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3\u00a0trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0290","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/SLA.0b013e31826b4dcc","article-title":"Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases","volume":"256","author":"Andreou","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0295","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0305","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.soc.2012.07.013","article-title":"Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy","volume":"21","author":"Van der Speeten","year":"2012","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0315","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","article-title":"Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study","volume":"46.","author":"Bakkers","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2019.06.014","article-title":"Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer","volume":"142","author":"Wisselink","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0325","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study","volume":"109","author":"Hompes","year":"2013","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0335","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3\u00a0study","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0340","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0345","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial","volume":"158","author":"Arjona-S\u00e1nchez","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0350","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0355","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1039\/C4MT00131A","article-title":"Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor","volume":"6","author":"Bianga","year":"2014","journal-title":"Metallomics"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0360","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CAD.0b013e3282f07791","article-title":"Exposure-response relationships for oxaliplatin-treated colon cancer cells","volume":"19","author":"Kirstein","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0365","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","article-title":"A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers","volume":"15","author":"Stewart","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0370","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jviscsurg.2019.08.002","article-title":"Management of colorectal peritoneal metastases: expert opinion","volume":"156","author":"Abboud","year":"2019","journal-title":"J Visc Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0375","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1245\/s10434-022-12990-3","article-title":"The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology","volume":"30","author":"Kusamura","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0380","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr Probl Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0385","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Go\u00e9r\u00e9","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0390","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr Probl Surg"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0395","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0400","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1038\/s41467-022-32198-z","article-title":"Molecular characterization of colorectal cancer related peritoneal metastatic disease","volume":"13","author":"Lenos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/pp-2020-0142","article-title":"Priorities, actions and risks in the COVID-19\u00a0pandemic: a flash SoMe survey among surgical oncologists","volume":"6","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/pp-2016-0018","article-title":"Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study","volume":"1","author":"Sgarbura","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0415","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s12885-018-4697-7","article-title":"Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II\/III trial - PACHA-01 (NCT02494973)","volume":"18","author":"Go\u00e9r\u00e9","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0420","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adhm.202000655","article-title":"Electrostatic intraperitoneal aerosol delivery of nanoparticles: proof of concept and preclinical validation","volume":"9","author":"Van de Sande","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0430","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.ejso.2018.10.226","article-title":"Oxaliplatin use in pressurized intraperitoneal aerosole chemotherapy(PIPAC) is safe and well tolerated: a multicenter study","volume":"45","author":"Sgarbura","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0435","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/AS9.0000000000000203","article-title":"Treatment response after Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of colorectal origin","volume":"3","author":"H\u00fcbner","year":"2022","journal-title":"Ann Surg Open"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0440","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1245\/s10434-020-09332-6","article-title":"Pressurized intraperitoneal aerosol chemotherapy enhanced by electrostatic precipitation (ePIPAC) for patients with peritoneal metastases","volume":"28","author":"Taibi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0445","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1245\/s10434-022-11577-2","article-title":"Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study","volume":"29","author":"Taibi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.10.006_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/pp-2022-0102","article-title":"Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"7","author":"Sgarbura","year":"2022","journal-title":"Pleura Peritoneum"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512300423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512300423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:25Z","timestamp":1757792305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512300423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S000745512300423X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.10.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La chimioth\u00e9rapie intra-p\u00e9riton\u00e9ale dans le traitement de la carcinose p\u00e9riton\u00e9ale d\u2019origine colorectale. CHIP, PIPAC, \u00e9tat des lieux et perspectives","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}